Ratings Moves: GES,...
Health Care: Drugs
Generex Biotechnology Corporation (GNBT: OTC)
$0.03 0.00 | 1.11%
05/21/13 - 03:38 PM ET
Company Income Statement
| Jul 2012 | Jul 2011 | Jul 2010 | Jul 2009 | |
| Sales | 28.65K | 291.63K | 1.17M | 1.12M |
| Cost of Sales | 11.11K | 155.62K | 812.27K | 527.73K |
| Gross Operating Profit | 17.54K | 136.01K | 360.34K | 590.78K |
| Selling, General, and Administrative Expenses | 5.05M | 14.42M | 16.43M | 13.29M |
| Research & Development | 4.99M | 10.25M | 13.36M | 13.56M |
| Operating Income before D & A (EBITDA) | -10.02M | -24.53M | -29.43M | -26.26M |
| Depreciation & Amortization | 1.22M | 1.68M | 2.55M | 16.75M |
| Interest Income | 1.52K | 6.46K | 27.04K | 237.98K |
| Other Income - Net | 1.12M | 3.06M | 4.33M | 320.55K |
| Special Income / Charges | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Income Before Interest Expenses (EBIT) | -10.11M | -23.15M | -27.62M | -42.45M |
| Interest Expense | 592.52K | 208.91K | 210.08K | 20.11M |
| Pre-Tax Income | -10.71M | -23.36M | -27.83M | -62.56M |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Continuing Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income From Total Operations | 0.00 | 0.00 | 0.00 | 0.00 |
| Extraordinary Income/Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Cum. Effect of Acct. Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Income From Tax Loss Carryforward | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Gains / Losses | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Net Income | -9.49M | -21.68M | -25.28M | -45.81M |
| Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge) |
0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends | ||||
|---|---|---|---|---|
| Net Income Available To Common | -376.75K | -766.42K | 0.00 | 0.00 |
| Basic EPS from Continuing Ops. | -0.03 | -0.08 | -0.10 | -0.32 |
| Basic EPS from Discontinued Ops. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Total Operations | -0.03 | -0.08 | -0.10 | -0.32 |
| Basic EPS from Extraordinary Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Tax Loss Carryf'd. | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS from Other Gains (Losses) | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic EPS, Total | -0.03 | -0.08 | -0.10 | -0.32 |
| Basic Normalized Net Income/Share | n.a. | n.a. | n.a. | n.a. |
| EPS fr Continuing Ops. | -0.03 | -0.08 | -0.10 | -0.32 |
| EPS fr Discontinued Ops | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Total Ops. | -0.03 | -0.08 | -0.10 | -0.32 |
| EPS fr Extraord. Inc. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Cum Effect of Accounting Change | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Tax Loss Carfd. | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS fr Other Gains (L) | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS, Total | -0.03 | -0.08 | -0.10 | -0.32 |
| Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge) |
n.a. | n.a. | n.a. | n.a. |
| Dividends Paid per Share | 0.00 | 0.00 | 0.00 | 0.00 |
Portfolios with GNBT
- Portfolio NameUser Type
- Userroy
- Userphospho
- Userjetpilot Portfolio 1
- UserEmerging biotech
- Userpdehenau Portfolio 1
- Usernvoelz Portfolio 1
- UserCER777 Portfolio 1
- UserDoc's Picks
- Usermy pikz
- Userterri cal
Latest GNBT Headlines from TheStreet
- Biotech Stock Mailbag: Generex 10.01.10 | 07:10 am
- Generex Oncology Announces Consultancy Of Dr. George E. Peoples, MD 09.02.10 | 09:09 am
- Generex Biotechnology Initiates Social Media Campaign For Its Corporate And E-Commerce Websites 09.01.10 | 09:09 am
- Generex Informs Stockholders Of Minimum Exchange Ratio For Reverse Stock Split Proposal To Be Considered At The Special Meeting Of Stockholders On September 17, 2010 08.27.10 | 04:08 pm
- Generex Oncology Names Dr. Craig Eagle To Its Scientific Advisory Board To Assist With Its Proprietary Cancer Vaccines Program 08.05.10 | 09:08 am
- Generex Biotechnology Creates Scientific Advisory Board To Further The Progression Of Its Drug Development Programs 08.02.10 | 09:08 am
- Generex Announces AGM Results 07.30.10 | 04:07 pm
- Generex Provides Positive Update On Generex Oral-Lyn(TM) Pivotal Phase III Trial 07.28.10 | 09:07 am
- Generex's Glucose RapidSpray(TM) Now Available At Boots UK Retail Chain Stores 07.15.10 | 09:07 am
- Generex Announces Receipt Of Favorable NASDAQ Listing Determination 07.15.10 | 07:07 am
Press Releases for GNBT
- Generex Comments On Results Of Stockholders` Meeting - PR Newswire 04.03.13 | 09:04 am
- Generex Touts Pipeline Potential Of Antigen Express Subsidiary - PR Newswire 02.07.13 | 09:02 am
- Generex Points To Potential Of Antigen Express Technology Platform Beyond Its AE37 Breast Cancer Vaccine - PR Newswire 01.31.13 | 09:01 am
- Generex Provides An Overview Of Its Cancer Immunotherapy Product, AE37, And Potential In Early Breast Cancer Given Current And Potential Future Therapies - PR Newswire 01.30.13 | 09:01 am
- Generex Announces Details Of Investor Conference Call - PR Newswire 01.29.13 | 09:01 am
- Generex Oral-lynâ¿¢ Phase III Dossier Submitted To Indian Government For Marketing Approval - PR Newswire 01.23.13 | 09:01 am
- Antigen Express AE37 Breast Cancer Vaccine Featured In "Micro-Cap Review" Interview - PR Newswire 01.17.13 | 09:01 am
- Generex Announces Investor Conference Call - PR Newswire 01.11.13 | 09:01 am
- Generex Announces $750,000 Capital Investment - PR Newswire 12.11.12 | 05:12 pm
- Generex Provides Update On Company Initiatives Including The AE37 Breast Cancer Vaccine Program - PR Newswire 11.13.12 | 09:11 am
Partner Headlines for GNBT
- Weekly CFO Sells Highlight: TDG, GNBT, ADGE, HFC, AMSWA - GuruFocus 07.02.12 | 05:07 pm
- Generex Announces Sales Agreement with Elias Shaker & Company (GNBT) - Benzinga 09.20.10 | 09:09 am
- Good News for Generex: Positive Data on Oral Insulin Coming in September - Seeking Alpha 08.16.10 | 08:08 am
- Generex: Reverse Split Not Approved - Seeking Alpha 08.01.10 | 08:08 am
- Four Small Caps for Binary Event Investors - Seeking Alpha 05.24.10 | 03:05 am
- Why Biodel is Breathing Easy, Part 2 - Seeking Alpha 05.03.10 | 05:05 pm
- Why Biodel is Breathing Easy, Part 1 - Seeking Alpha 05.03.10 | 05:05 pm
- Generex's Insulin Product: When a Company Misrepresents 'Compassionate Use' - SeekingAlpha.com 04.29.10 | 11:04 am
- Generex's Antigen Express: Creating the Next Generation of Cancer Immunotherapy - SeekingAlpha.com 04.14.10 | 04:04 am
- Tengion's IPO Comes In Well Below Initial Range: Biotech's Latest Deals, Financings - SeekingAlpha.com 04.11.10 | 08:04 am
